Skip to main content

Table 2 Multiple designs of targeting nanodrugs for HER2-positive breast cancer

From: Nanotechnology approaches to addressing HER2-positive breast cancer

Nanoparticle

Targeting mechanism

Cancer therapy

Multifunction capability

References

Pluronic-based nanocarrier loaded with iron oxide nanoparticles

Chitosan conjugated/HER2 targeting

Doxorubicin

Iron oxide for MRI imaging, Cy5.5 for imaging, doxorubicin for anticancer therapy

Choi et al. (2015)

PEGylated phospholipid nanobubble

Herceptin targeting HER2 receptors

None

Can potentially deliver anticancer therapy, has ultrasonography capability for imaging

Jiang et al. (2016)

Mini-nanodrug, co-ligand poly(beta-L-malic acid) (PMLA)

HER2-mRNA-annealing oligonucleotide

None

Functionalization for drugs, targeting peptides, protective PEG, peptides for destabilizing membranes and dyes for imaging

Ding et al., 2017

Novel humanized HER2 antibody

Anti-HER2 antibody

None

Can be used in many targeting applications. Has advantages over traditional antibodies

Cao et al. (2015)

HER2 aptamer-conjugated gold nanostar

42-base pair HER2 aptamer for targeting HER2 receptors

Reduction of HER2 receptors due to lysosome degradation

This HER2 aptamer gold nanostar can be used for detection while offering drug delivery

Lee et al. (2015)

Antibody-conjugated gold–gold sulfide nanoparticle

Anti-HER2 antibody conjugated for targeting HER2 receptors

Photothermal therapy

Simultaneously provides targeting contrast agents for imaging and photothermal therapy

Day et al. (2010)

Iron oxide nanoparticle

Small exocyclic peptide from the 185HER2/neu monoclonal antibody trastuzumab. conjugated for targeting HER2 receptors

Paclitaxel

None

Mu et al. (2015)